Clinical trials: T-cell Lymphoblastic Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
The stud will evaluate whether infusions of CD45RA-depleted lymphocytes from the donor early post-transplant is a safe way to improve immunity to common infections in recipients of TCR-alpha/beta depleted hematopoietic stem cell…
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Immune Deficiency Disease, Bone Marrow Failure Syndromes
- Trial name
- 45RA_NEG_DLI (NCT02337595)
- Testing
- CD45RA-depleted peripheral blood mononuclear cells
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
RATIONALE: Questionnaires that measure quality-of-life may improve the health care team's ability to plan supportive care for patients undergoing donor bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281801
- Testing
- psychosocial assessment and care, Quality of Life Assessments
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Case Comprehensive Cancer Center
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
This phase Ib trial investigates the side effects and best dose of pegcrisantaspase when given together with fludarabine and cytarabine for the treatment of patients with leukemia that has come back (relapsed) or has not…
- Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT04526795
- Testing
- Cytarabine, Fludarabine, Pegcrisantaspase
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia
- Trial name
- Orca-T (NCT05316701)
- Testing
- Orca-T, Standard-of-Care
- Where
- 19 sites in United States
- Volunteers
- 187 people
- Sponsor
- Orca Biosystems, Inc.
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit which, upon expression, is…
- Conditions
- Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04323657
- Testing
- TC-110 T Cells, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- TCR2 Therapeutics
Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia
Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier.
- Trial name
- NCT05044039
- Testing
- Duvelisib, CAR T-cells
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
This is a multi-centers, single-arm, open label, Phase 2 clinical trial to evaluate the efficacy and safety of CD7 CAR T cells in subjects with relapsed or refractory T-cell leukemia/lymphoma. Seventy subjects will be enrolled.
- Conditions
- T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence
- Trial name
- NCT04689659
- Testing
- chimeric antigen receptor T cell treatment
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Beijing Boren Hospital
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
This pilot clinical trial studies low-dose total body irradiation and donor peripheral blood stem cell transplant followed by donor lymphocyte infusion in treatment patients with non-Hodgkin lymphoma, chronic lymphocytic…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT00003196
- Testing
- chemotherapy, total-body irradiation, peripheral blood stem cell transplantation
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 63 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
This phase II trial studies how well alisertib works in treating patients with peripheral T-cell non-Hodgkin lymphoma that has come back after a period of improvement or has not responded to treatment.
- Conditions
- Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma
- Trial name
- NCT01466881
- Testing
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 161 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about diagnosing cancer and determine a patient's eligibility for a treatment…
- Trial name
- NCT00897767
- Testing
- biologic sample preservation procedure
- Where
- 214 sites in United States
- Volunteers
- 1,873 people
- Sponsor
- Eastern Cooperative Oncology Group
Cardiac Toxicity, Leukemia
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Cardiac Toxicity, Leukemia, Lymphoma
- Trial name
- T-Cell #4 (NCT01230983)
- Testing
- asparaginase, cytarabine, dexrazoxane hydrochloride
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
Phase I trial to study genetic testing and the effectiveness of irinotecan in treating patients who have solid tumors and lymphoma.
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00003970
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
ALL, Burkitt's Lymphoma
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
Assess the safety, tolerability and efficacy of rapamycin in combination with HiVAC in relapsed and refractory patients with aggressive lymphoid malignancies.
- Conditions
- ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia, CML
- Trial name
- UPCC 25406 (NCT00776373)
- Testing
- Rapamycin, High dose etoposide and cytarabine (HiVAC)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
B Acute Lymphoblastic Leukemia, CD19 Positive
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy and NKTR-255, and to see how well they work in treating patients with CD19 positive B acute…
- Conditions
- B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
- Trial name
- NCT03233854
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Stanford University
Leukemia
Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00707083
- Testing
- dexamethasone, mercaptopurine, methotrexate
- Where
- 2 sites in China
- Volunteers
- 2,231 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Chronic Myeloproliferative Disorders, Leukemia
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
This phase I trial is studying the side effects and best dose of decitabine and FR901228 in treating patients with relapsed or refractory leukemia, myelodysplastic syndromes or myeloproliferative disorders.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00114257
- Testing
- decitabine, romidepsin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
This phase I trial tests the safety and side effects of B-cell activating factor receptor (BAFFR) chimeric antigen receptor (CAR) T cells and how well they work in treating patients with B-cell acute lymphoblastic leukemia…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
- Trial name
- NCT07758673
- Testing
- Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Lymphoma, Small Intestine Cancer
17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
RATIONALE: Drugs used in chemotherapy, such as 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00088868
- Testing
- alvespimycin hydrochloride
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Leukemia
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00430118
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 76 sites in Austria, Germany and 1 more
- Volunteers
- 4,559 people
- Sponsor
- University Hospital Schleswig-Holstein
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.